ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
9.99
+0.24 (2.46%)
Oct 8, 2026, 2:14 PM EDT - Market open
ImmunityBio Employees
As of December 31, 2025, ImmunityBio had 691 total employees, including 684 full-time and 7 part-time employees. The number of employees increased by 11 or 1.62% compared to the previous year. That makes ImmunityBio the 17,619th largest employer in the world and 2,444th in the United States.
Employees
691
Change
11
Growth
1.62%
Revenue / Employee
$239,931
Profits / Employee
-$1,436,117
Market Cap
10.59B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 691 | 11 | 1.62% | 684 | 7 |
| Sep 30, 2025 | 673 | 1 | 0.15% | 673 | 0 |
| Jun 30, 2025 | 685 | 63 | 10.13% | 685 | 0 |
| Mar 31, 2025 | 671 | 43 | 6.85% | 671 | 0 |
| Dec 31, 2024 | 680 | 52 | 8.28% | 680 | 0 |
| Sep 30, 2024 | 672 | 2 | 0.30% | 672 | 0 |
| Jun 30, 2024 | 622 | -61 | -8.93% | 622 | 0 |
| Mar 31, 2024 | 628 | -75 | -10.67% | 628 | 0 |
| Dec 31, 2023 | 628 | -97 | -13.38% | 628 | 0 |
| Sep 30, 2023 | 670 | -90 | -11.84% | 670 | 0 |
| Jun 30, 2023 | 683 | -57 | -7.70% | 683 | 0 |
| Mar 31, 2023 | 703 | 15 | 2.18% | 703 | 0 |
| Dec 31, 2022 | 725 | 138 | 23.51% | 725 | 0 |
| Sep 30, 2022 | 760 | 222 | 41.26% | 760 | 0 |
| Jun 30, 2022 | 740 | 229 | 44.81% | 740 | 0 |
| Mar 31, 2022 | 688 | 213 | 44.84% | 688 | 0 |
| Dec 31, 2021 | 587 | 138 | 30.73% | 587 | 0 |
| Sep 30, 2021 | 538 | 273 | 103.02% | 538 | 0 |
| Jun 30, 2021 | 511 | 246 | 92.83% | 511 | 0 |
| Mar 31, 2021 | 475 | 210 | 79.25% | 475 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,000 |
| Axsome Therapeutics | 1,346 |
| Twist Bioscience | 979 |
| Madrigal Pharmaceuticals | 915 |
| Arrowhead Pharmaceuticals | 711 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
IBRX News
- 5 hours ago - ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium - Business Wire
- 6 days ago - ImmunityBio rises 12.4% - TheFly
- 6 days ago - ImmunityBio rises 11.6% - TheFly
- 8 days ago - ImmunityBio rises 12.3% - TheFly
- 4 weeks ago - ImmunityBio put volume heavy and directionally bearish - TheFly
- 1 month ago - ImmunityBio appoints Kim as Vice Chairman - TheFly
- 1 month ago - ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman - Business Wire
- 2 months ago - ImmunityBio reports Q2 EPS (22c) vs. (10c) last year - TheFly